AU2002336749A1 - Tricyclic indole derivatives as 5-ht ligands - Google Patents

Tricyclic indole derivatives as 5-ht ligands

Info

Publication number
AU2002336749A1
AU2002336749A1 AU2002336749A AU2002336749A AU2002336749A1 AU 2002336749 A1 AU2002336749 A1 AU 2002336749A1 AU 2002336749 A AU2002336749 A AU 2002336749A AU 2002336749 A AU2002336749 A AU 2002336749A AU 2002336749 A1 AU2002336749 A1 AU 2002336749A1
Authority
AU
Australia
Prior art keywords
ligands
indole derivatives
tricyclic indole
tricyclic
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002336749A
Other languages
English (en)
Inventor
Jian-Min Fu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of AU2002336749A1 publication Critical patent/AU2002336749A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2002336749A 2001-09-21 2002-09-19 Tricyclic indole derivatives as 5-ht ligands Abandoned AU2002336749A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32366601P 2001-09-21 2001-09-21
US60/323,666 2001-09-21
PCT/US2002/030089 WO2003024976A2 (en) 2001-09-21 2002-09-19 Tricyclic indole derivatives as 5-ht ligands

Publications (1)

Publication Number Publication Date
AU2002336749A1 true AU2002336749A1 (en) 2003-04-01

Family

ID=23260193

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002336749A Abandoned AU2002336749A1 (en) 2001-09-21 2002-09-19 Tricyclic indole derivatives as 5-ht ligands

Country Status (8)

Country Link
US (1) US6887868B2 (enExample)
EP (1) EP1429776A2 (enExample)
JP (1) JP2005527477A (enExample)
AU (1) AU2002336749A1 (enExample)
BR (1) BR0212676A (enExample)
CA (1) CA2460126A1 (enExample)
MX (1) MXPA04002615A (enExample)
WO (1) WO2003024976A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
AR059356A1 (es) * 2006-02-14 2008-03-26 Astrazeneca Ab Nuevos radioligandos
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
US9216998B2 (en) * 2012-02-15 2015-12-22 Janssen Pharmaceutica Nv Tricyclic indole derivatives useful endothelial lipase inhibitors
RU2764243C2 (ru) * 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
RS65576B1 (sr) 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4219550A (en) * 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US4985420A (en) * 1987-12-10 1991-01-15 Duphar International Research B.V. 1,7-annelated indolecarboxylic acid esters and -amides
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
NZ233285A (en) 1989-04-18 1992-06-25 Duphar Int Res Imidazole-substituted carbamoyl-indoles and condensed analogues thereof and pharmaceutical compositions
GB8913646D0 (en) 1989-06-14 1989-08-02 Glaxo Group Ltd Chemical compounds
HUT61548A (en) 1990-08-27 1993-01-28 Sandoz Ag Process for producing indolonaphthyridine derivatives and pharmaceutical compositions comprising such compounds
HUP0103381A3 (en) 1998-07-30 2002-07-29 Japan Tobacco Inc Disubstituted maleimide compounds and medicinal utilization thereof and the pharmaceutical compositions containing the same
PE20010052A1 (es) 1999-04-23 2001-01-27 Upjohn Co Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht
WO2000077001A1 (en) * 1999-06-15 2000-12-21 Du Pont Pharmaceuticals Company Substituted heterocycle fused gamma-carbolines

Also Published As

Publication number Publication date
JP2005527477A (ja) 2005-09-15
BR0212676A (pt) 2006-05-23
EP1429776A2 (en) 2004-06-23
WO2003024976A2 (en) 2003-03-27
WO2003024976A3 (en) 2004-02-12
MXPA04002615A (es) 2004-07-08
US6887868B2 (en) 2005-05-03
US20030087883A1 (en) 2003-05-08
CA2460126A1 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
IL162105A0 (en) New indole derivatives as factor xainhibitors
AU5049699A (en) Phenylindole derivatives as 5-HT2A receptor ligands
AU2001231664A1 (en) Indol-3-yl derivatives
AU5633300A (en) Indole compounds
AU7947000A (en) Tricyclic fused-imidazole derivatives
IL160043A0 (en) Process for the preparation of indole derivatives
AU2001259051A1 (en) Piperidyindoles as serotonin receptor ligands
AU2001270822A1 (en) Imidazolophthalazine derivatives as ligands for gabaa receptors
AU2001295455A1 (en) Indoline derivatives as 5ht2c antagonists
AU2002346507A1 (en) Benzazepine derivatives and their use as 5-ht ligands
AU1339301A (en) Novel indole compounds
AU2003217817A1 (en) Pyridinyloxy derivatives as 5-ht receptor ligands
AU2002328894A1 (en) Substituted 4-aminocyclohexanol derivatives
AU2003209114A1 (en) Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
PL366520A1 (en) Novel indole derivatives
AU5633800A (en) Indole compounds
AU2002332480A1 (en) Tetracyclic indole derivatives as 5-ht receptor ligands
AU2001286259A1 (en) Tricyclic indole compounds having affinity for serotonin receptor
AU2002248321A1 (en) Substituted indolines as 5-ht receptor ligands
AU2002354499A1 (en) Indole derivative
AU2003270669A1 (en) Cyclopentyl indole derivatives
AU3634001A (en) Indole compounds
AU2002332147A1 (en) Indole derivatives
HK1060880A (en) Heterocyclylalkoxy-, -alkylthio- and - alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
HK1060128A (en) Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase